journal article·2022-02-09

Biomineralized Cascade Enzyme-Encapsulated ZIF-8 Nanoparticles Combined with Antisense Oligonucleotides for Drug-Resistant Bacteria Treatment

Yan Zhang, Luogen Lai, Yijun Liu, Beini Chen, Jing Yao, Pengwu Zheng, Qingshan Pan, Wufu Zhu

Publisher page

Abstract

The unrestrained use of antibiotics accelerates the development of drug-resistant bacteria and leads to an increasing threat to human health. Therefore, there is an urgent need to explore novel and effective strategies for the treatment of bacterial infections. Herein, zeolite imidazole framework-8 (ZIF-8) material was utilized to construct biomineralized nanomaterial (GOx&HRP@ZIF-8/ASO) by encapsulating biological cascade enzymes and combining with antisense oligonucleotides (ASOs), which achieved effective and synergistic antidrug-resistant bacteria therapy. Various in vitro assays confirmed that GOx&HRP@ZIF-8/ASO exhibited excellent antibacterial properties against Escherichia coli, Staphylococcus aureus, methicillin-resistant S. aureus (MRSA) during catalysis of glucose (Glu), especially the minimum inhibitory concentration (MIC) against MRSA was only 16 μg/mL. Compared with simple ZIF-8 (32.85%) and ftsZ ASO (58.65%), GOx&HRP@ZIF-8/ASO+Glu exhibited superb biofilm destruction ability, and the bacteria removal efficiency of the MRSA biofilm could be as high as 88.2%, indicating that the reactive oxygen species (ROS) produced by the cascade enzyme reaction imparted the main synergistic antibacterial capability, and simultaneously, ftsZ ASO significantly enhanced the antibacterial effect by inhibiting the expression of the ftsZ gene. In vivo anti-infection treatment experiments revealed that GOx&HRP@ZIF-8/ASO exhibited the best wound repairing performance and excellent biocompatibility in the presence of Glu. These findings suggested that GOx&HRP@ZIF-8/ASO has favorably realized high-efficiency treatment of MRSA infection and filled the gap in the antibacterial application of biological enzymes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Antimicrobial Peptides and Activities · Antimicrobial agents and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, Jiangxi, China

Funding

Education Department of Jiangxi Province · National Natural Science Foundation of China · Jiangxi Science and Technology Normal University · Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, Jiangxi Science and Technology Normal University · College Student Innovation and Entrepreneurship Training Program

References (62)

Show source-provided references
1. 10.1093/jac/dkm35710.1093/jac/dkm357 ↗
2. 10.1007/s11908-012-0299-810.1007/s11908-012-0299-8 ↗
3. 10.1038/s41579-020-00469-510.1038/s41579-020-00469-5 ↗
4. 10.1016/j.envres.2020.10999510.1016/j.envres.2020.109995 ↗
5. 10.1093/cid/ciaa133910.1093/cid/ciaa1339 ↗
6. 10.1016/S1473-3099(18)30605-410.1016/S1473-3099(18)30605-4 ↗
7. 10.3389/fcimb.2020.0031410.3389/fcimb.2020.00314 ↗
8. 10.1007/s10096-020-04123-z10.1007/s10096-020-04123-z ↗
9. 10.1016/j.biomaterials.2018.10.03010.1016/j.biomaterials.2018.10.030 ↗
10. 10.1007/s11739-021-02749-110.1007/s11739-021-02749-1 ↗
11. 10.1016/j.jmmm.2005.01.06410.1016/j.jmmm.2005.01.064 ↗
12. 10.1016/j.biomaterials.2020.11998310.1016/j.biomaterials.2020.119983 ↗
13. 10.1007/s12274-018-2179-510.1007/s12274-018-2179-5 ↗
14. 10.1002/adtp.20170003310.1002/adtp.201700033 ↗
15. 10.1016/j.addr.2021.11394810.1016/j.addr.2021.113948 ↗
16. 10.1039/c0cc05002d10.1039/c0cc05002d ↗
17. 10.1016/j.cej.2015.02.09410.1016/j.cej.2015.02.094 ↗
18. 10.1016/j.biomaterials.2019.11947310.1016/j.biomaterials.2019.119473 ↗
19. 10.1021/acsami.0c1549410.1021/acsami.0c15494 ↗
20. 10.1016/j.biomaterials.2021.12086910.1016/j.biomaterials.2021.120869 ↗
21. 10.1016/j.cej.2020.12751110.1016/j.cej.2020.127511 ↗
22. 10.1002/adfm.20180001110.1002/adfm.201800011 ↗
23. 10.1038/s41467-019-10218-910.1038/s41467-019-10218-9 ↗
24. 10.1002/adfm.20190938910.1002/adfm.201909389 ↗
25. 10.1021/jacs.8b0445710.1021/jacs.8b04457 ↗
26. 10.1002/anie.20181306010.1002/anie.201813060 ↗
27. 10.1021/acsami.9b2352610.1021/acsami.9b23526 ↗
28. 10.1002/adma.20200517210.1002/adma.202005172 ↗
29. 10.1021/acssuschemeng.9b0234810.1021/acssuschemeng.9b02348 ↗
30. 10.1002/adma.20190117910.1002/adma.201901179 ↗
31. 10.1039/D0SC00339E10.1039/D0SC00339E ↗
32. 10.1039/C5CC05136C10.1039/C5CC05136C ↗
33. 10.1016/j.cej.2019.01.13810.1016/j.cej.2019.01.138 ↗
34. 10.1002/anie.20191323110.1002/anie.201913231 ↗
35. 10.1038/s41467-019-12966-010.1038/s41467-019-12966-0 ↗
36. 10.1038/s41467-018-08234-210.1038/s41467-018-08234-2 ↗
37. 10.1016/j.redox.2020.10152410.1016/j.redox.2020.101524 ↗
38. 10.1146/annurev.med.55.091902.10440810.1146/annurev.med.55.091902.104408 ↗
39. 10.1007/s12265-013-9495-710.1007/s12265-013-9495-7 ↗
40. 10.1016/j.biomaterials.2018.12.03310.1016/j.biomaterials.2018.12.033 ↗
41. 10.1021/acsami.8b1828810.1021/acsami.8b18288 ↗
42. 10.1158/0008-5472.CAN-18-094110.1158/0008-5472.CAN-18-0941 ↗
43. 10.1002/anie.20201117410.1002/anie.202011174 ↗
44. 10.1186/s12951-020-00667-610.1186/s12951-020-00667-6 ↗
45. 10.1021/acs.nanolett.0c0052910.1021/acs.nanolett.0c00529 ↗
46. 10.1038/s41598-018-28015-710.1038/s41598-018-28015-7 ↗
47. 10.1038/nrm174510.1038/nrm1745 ↗
48. 10.1128/MMBR.00021-1010.1128/MMBR.00021-10 ↗
49. 10.3390/antibiotics804021710.3390/antibiotics8040217 ↗
50. 10.1021/acsinfecdis.9b0005510.1021/acsinfecdis.9b00055 ↗
51. 10.1021/acs.nanolett.5b0049010.1021/acs.nanolett.5b00490 ↗
52. 10.1016/j.jconrel.2021.01.00110.1016/j.jconrel.2021.01.001 ↗
53. 10.1016/j.ijid.2014.09.01510.1016/j.ijid.2014.09.015 ↗
54. 10.1002/anie.20210771210.1002/anie.202107712 ↗
55. 10.1038/nprot.2007.52110.1038/nprot.2007.521 ↗
56. 10.1016/j.ijbiomac.2019.11.12910.1016/j.ijbiomac.2019.11.129 ↗
57. 10.1063/1.235630710.1063/1.2356307 ↗
58. 10.1016/j.elecom.2007.12.01110.1016/j.elecom.2007.12.011 ↗
59. 10.1016/j.cej.2020.12547110.1016/j.cej.2020.125471 ↗
60. 10.3390/microorganisms501000910.3390/microorganisms5010009 ↗
61. 10.1016/j.biomaterials.2021.12077510.1016/j.biomaterials.2021.120775 ↗
62. 10.1021/acsami.7b0277510.1021/acsami.7b02775 ↗